Form 4: Sarepta Therapeutics CFO Ian Estepan Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
Chief Financial Officer of Sarepta Therapeutics, Ian Michael Estepan, reports the sale of 557 shares of common stock to cover tax withholding obligations related to vesting of restricted stock units.
Summary
- Ian Michael Estepan, the Chief Financial Officer of Sarepta Therapeutics, reported a transaction involving the sale of company stock on March 3, 2025.
- The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units granted on March 1, 2024.
- A total of 557 shares of common stock were sold at a price of $103.77 per share.
- Following the transaction, Estepan directly owns 46,326 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine transaction related to tax obligations, so it has a neutral sentiment.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common practice to sell a portion of shares to cover tax obligations upon vesting.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of grant for restricted stock units related to the tax withholding. |
| 03/03/2025 | Date of stock sale transaction. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.